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ABSTRACT  
Introduction: Endometriosis is an estrogen-dependent chronic inflammatory disorder that requires 
a life-long management plan. Long-term adherence to treatment is pivotal to ensure an effective 
clinical management. In this optic, one of the cornerstone of endometriosis medical treatment is 
represented by progestins. 
Areas covered: This narrative review examines the clinical efficacy, safety and tolerability of oral 
and depot progestins used in the treatment of endometriosis. The material included in the current 
manuscript was obtained with a MEDLINE search through PubMed from inception until January 
2017. 
Expert opinion: Progestins are effective in controlling pain symptoms in the majority of women 
with endometriosis, and their effect seems not inferior to that achieved with other compounds used 
to treat the disease, such as gonadotropin-releasing hormone agonist. Available progestins include a 
broad range of both oral and depot compounds, and represent, in most cases, an inexpensive 
treatment option. In addition, progestins do not increase significantly thrombotic risk and could be 
adopted in those women with metabolic or cardiovascular contraindication to estrogen-progestins. 
The choice between the different available compounds should be tailored for every woman with 
preference to the most cost-effective treatment, depending on the most complained symptom and 
disease location. 
 
KEYWORDS: desogestrel; dienogest; endometriosis; levonorgestrel-intrauterine device; 
medroxyprogesterone acetate; medical therapy; norethisterone acetate; progestin 
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1. INTRODUCTION 
Endometriosis is a chronic inflammatory gynecological disorder associated with pelvic pain 
symptoms and infertility [1]. Endometriosis affects about 5% of women of reproductive age [2]. 
Women with endometriosis are at increased risk of abdominopelvic chronic pain, dysmenorrhea and 
deep dyspareunia compared to controls without the disease [3]. The origin of pain associated with 
endometriosis can be referred to different pathogenic mechanisms, such as increased production of 
pro-inflammatory cytokines and growth factors by activated macrophages and other cells associated 
with endometriotic implants, active bleeding from endometriotic lesions, and irritation or direct 
invasion of pelvic floor nerves by infiltrating endometriotic implants [4,5].   
 As suggested by the Practice Committee of the American Society for Reproductive 
Medicine (ASRM): “endometriosis should be viewed as a chronic disease that requires a life-long 
management plan with the goal of maximizing the use of medical treatment and avoiding repeated 
surgical procedures” [6]. However, patients with endometriosis represent an extremely 
heterogeneous population regarding both symptoms severity and anatomic abnormalities [1]. In 
addition, not only the efficacy, but also the long-term tolerability and costs of the treatments should 
be taken into account. Long-term adherence to treatment is pivotal to ensure an effective clinical 
management. In this optic, a tailored patient management appears of primary importance, with the 
aim of identifying the specific issue and the appropriate treatment for every woman.  
 One of the cornerstone of endometriosis medical treatment is represented by progestins [1]. 
Progestins are synthetic compounds that mimic the effects of progesterone [7]. They can inhibit 
inflammatory pathways and responses, and provoke apoptosis in endometriotic cells [8]. In 
addition, progestins are able to reduce oxidative stress, through the reduction or the abolishment of 
uterine bleeding [9]. Moreover, this class of drug stimulate atrophy or regression of endometrial 
lesions, induce anovulation, inhibit angiogenesis, and decrease expression of matrix 
metalloproteinases, thus diminishing the invasiveness of endometriotic implants [7,10]. Finally, 
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they reduce the frequency and augment the amplitude of pulsatile gonadotropin-releasing hormone 
(GnRH) release; this leads to a reduced secretion of follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) [7] with the establishment of a hypo-estrogenic milieu that could 
suppress endometriosis and prevent progression of the disease [10]. 
 Numerous progestins compounds are used in the treatment of endometriosis; they can be 
administered via an oral, intramuscular/subcutaneous, intrauterine or subdermal route [1] (Table 1). 
In the endometriosis field, progestins are increasingly used as a monotherapy with great results 
[1,10]. Major advantages of these drugs are that they do not increase the thrombotic risk and can be 
safely used in those women with contraindication to estrogens [11] or in those who do not tolerate 
estrogens [12].  
METHODOLOGY 
 In this narrative review, we aimed to provide a comprehensive overview of the role of both 
oral and depot progestins in the treatment of endometriosis, analyzing the pros and cons of every 
compound. We have included in our manuscript only those progestins specifically adopted for the 
treatment of endometriosis.  For this review, the best quality evidence was selected with preference 
given to the most recent and definitive original articles and reviews. Information was identified by 
searches of MEDLINE and references from relevant articles, using combinations of MESH terms 
“endometriosis”, “progestin”, “progestin therapy”, “medical therapy”, “norethisterone acetate”, 
“norethindrone acetate”, “dienogest”, “desogestrel”, “cyproterone acetate”, “medroxyprogesterone 
acetate”, “depot medroxyprogesterone acetate”, “levonorgestrel intrauterine device”, and 
“etonogestrel”. The search was limited to peer-reviewed, full-text articles in the English language. 
For most issues, papers published between June 1989 and February 2017 were considered. 
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2. ORAL PROGESTINS 
2.1 NORETHISTERONE ACETATE  
Norethisterone acetate (or norethindrone acetate, NETA) is a strong derivative of 19-nor-
testosterone. Continuous use, at the lowest dose of 5 mg/d, is approved by the US Food and Drug 
Administration (FDA) for the treatment of endometriosis. However, numerous studies by 
independent groups demonstrated the efficacy of a reduced daily dose of 2.5 mg [13-16]. The lower 
dosage increases the tolerability, reducing weight gain and androgenic side effects, and limits the 
negative impact on serum cholesterol values [13]. In addition, NETA is partly metabolized to 
estrogens [17,18], with subsequent positive effects on bone metabolism. Another major advantage 
of NETA is its cost, in fact, in Italy, the monthly cost of treatment with 2.5 mg/d is less than 2 US $ 
[13]. 
 Several studies demonstrated the beneficial effects of NETA in the management of 
symptomatic endometriosis. In 1998 Muneyyirci-Delale and Karakan [19] treated 52 women with 
surgically confirmed endometriosis with NETA at a daily dosage of 5 mg, which was increased by 
2.5 mg up to 20 mg/d until amenorrhea was obtained. Overall, pain relief was achieved in 49/52 
(94%) of patients, with a discontinuation rate of 15% (n = 8). The most common side effect was 
breakthrough bleeding, reported by 30 women (58%), that led to drop out in 4 (8%) patients.  
 The favorable impact of NETA on endometriosis symptoms was confirmed by Vercellini et 
al. [13] in a randomized trial comparing NETA, at a daily dosage of 2.5 mg, and an estrogen-
progestin (EP) combination (ethinyl estradiol (EE) 0.01 mg + cyproterone acetate 3 mg). Both 
therapies were administered continuously for 12 months. Only patients with symptomatic 
rectovaginal endometriosis were enrolled (n = 90). Overall, 73% women in the NETA group were 
satisfied or very satisfied with treatment compared to 62% in the EP group. Both treatments were 
equally effective in the management of pain symptoms and on the reduction of lesion size at 
ultrasound. Both regimens caused minor unfavorable changes in the serum lipid profile. Weight 
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gain (27%; mean weight gain 3.6 +/- 2.3 kg) and decreased libido (9%) were the most frequent 
reported side effects in NETA treatment group.  
 In 2010, Ferrero et al. [14] performed a pilot study on the efficacy of NETA in the treatment 
of pain and gastrointestinal symptoms in 40 women with colorectal endometriosis. Patients received 
NETA 2.5 mg/d for 12 months, in case of persistent breakthrough bleeding patients were instructed 
to increase the dose to a 5 mg/d. The satisfaction rate was good (60%), more than half of the 
patients reported an improvement in gastrointestinal symptoms and an amelioration of chronic 
pelvic pain and deep dyspareunia. The study was completed by 32 patients (80%), the most frequent 
cause of interruption was weight gain (n = 2; 5%).  
 Kaser et al. [20] successfully tested NETA in a population of adolescents and young adults 
(n = 194) with histologically confirmed endometriosis. In this retrospective study, women were 
treated with higher dose of NETA (5-15 mg/d). 65% of the patients reported a reduction in pain 
scores. Confirming previous data, the most common side effect associated with NETA 
administration was weight gain (16%).   
 In 2012, continuous low-dose progestin therapy (NETA 2.5 mg/d) and surgical therapy for 
endometriosis-associated deep dyspareunia were compared in a patient-preference parallel cohort 
study with a 12-month follow-up [15,16]. Only women with severe deep dyspareunia were enrolled. 
A total of 154 patients were included in the study, 51 chose surgery and 103 progestin treatment. In 
the surgery group dyspareunia’s improvement was marked and rapid, followed by partial recurrence 
of pain. Instead, in progestin group pain relief was more gradual but progressive throughout the 
whole study period. In addition, at the end of follow-up, patients treated with medical therapy 
reported a greater increase in the frequency of intercourse per month. Satisfaction rate was 
statistically significantly higher in the progestin group (59% versus 43%). At 1-year follow-up, 
NETA performed better than surgery in women without deep lesions, whereas in those with 
rectovaginal endometriosis, the two treatments showed comparable efficacy [15]. One of the major 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ità
 de
gli
 St
ud
i d
i M
ila
no
] a
t 0
9:4
3 1
5 S
ep
tem
be
r 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
   7
drawbacks and potential source of selection bias of this study is the non-random allocation of 
treatments, as the choice between surgery and medical treatment was based on patient’s preference.  
 Progestin therapies with NETA and dienogest (DNG) were directly compared by Vercellini 
et al. in 2016 [21]. The authors chose a before-after study design, in order to investigate the 
effectiveness (which of the two compounds performed better in real life) of the treatments. NETA 
has been shown to be as effective as DNG for pain relief, psychological status, sexual functioning 
and health-related quality of life (QoL). The proportion of satisfied plus very satisfied women after 
6 months of treatment was almost identical between the two study groups (71% in NETA group 
versus 72% in DNG group). In this Italian study, DNG was better tolerated than NETA, but much 
higher cost limited its acceptance by the patients. 
2.2 DIENOGEST  
Dienogest (DNG) is a fourth-generation selective progestin that combines the pharmacological 
properties of 19-nortestosterone and of progesterone derivatives. When administered at the dosage 
indicated for the management of endometriosis (2 mg/d), DNG inhibits the production of 
gonadotropin with a decrease in the endogenous release of estradiol, with the establishment of a 
hypoestrogenic and hyperprogestinic environment that stimulates initial decidualization and 
subsequent atrophy of endometriotic lesions [22]. However, during DNG treatment (at a daily dose 
of 2 mg) the average estradiol (E2) serum levels remain in the range of 20-50 pg/ml; this E2 serum 
concentration should, at the same time, prevent bone mineral density (BMD) loss and avoid 
endometriotic lesions growth [22]. Moreover, DNG exerts strong antiandrogenic properties, 
whereas it has no glucocorticoid nor mineral corticoid effects [22,23]. 
 However, regarding bone mineral density (BMD), the available data are inconsistent. In a 
recent study Lee et al. [24] have compared DNG (2 mg/d) with gonadotropin-releasing hormone 
agonist (GnRHa) with add-back (NETA 0.5 mg/d or estradiol 1 mg/d) therapy for the treatment of 
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endometriosis reporting a decline BMD at the lumbar spine in both treatment groups (-2.3% for 
DNG and -2.5% for GnRHa plus add-back). These data are in line with those of Momoeda et al. 
[25] that showed a significantly decrease (-1.6%) of lumbar spine BMD after 24 weeks of DNG 
treatment in patients with endometriosis. On the contrary, Strowitzki et al. [26] observed minimal 
changes in bone turnover markers and lumbar spine BMD after 6 months of DNG treatment.  
 DNG clinical efficacy has been investigated in studies against placebo [27], GnRH analogs 
[24,26,28-30], oral medroxyprogesterone acetate [31], and NETA [21,32] (Table 2). No randomized 
controlled trials (RCTs) assessing the effectiveness of DNG compared with combined oral 
contraceptives or with other progestins have been performed.  Overall, a daily dose of 2 mg DNG 
has been significantly better than placebo in relieving pelvic pain and dysmenorrhea related to 
endometriosis and as effective as GnRH agonist therapy in relieving pain [33].  
 In 2014, Morotti et al. [32] evaluated patients’ satisfaction after 6 months of treatment with 
DNG in 25 symptomatic women with rectovaginal endometriosis, who were non-responders to 
NETA.  DNG performed better than NETA both in terms of pain relief and in terms of 
improvement of quality of life and quality of sexual life, evaluated, respectively, with the EHP-30 
and FSFI questionnaires. No changes of volume of the rectovaginal plaques (endometriosis 
infiltrating the posterior vaginal and anterior rectal walls) were observed during treatment with 
DNG. These encouraging results were not confirmed in the comparative study between NETA and 
DNG that was discussed above [21].  
 The beneficial role of DNG in the improvement of QoL and sexual functions in women with 
symptomatic endometriosis has been confirmed by Caruso et al. [34], who enrolled 102 
endometriotic patients, assigning them to DNG treatment (n = 54) or non-steroidal anti-
inflammatory drugs (n = 48), the study period lasted 6 months. Patients were evaluated after 3- 
(first follow-up) and 6-months of treatment. Women in DNG group reported a significant 
amelioration compared to control group in pain symptoms and QoL at the first follow-up, and in 
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sexual life at the second follow-up. This latter element could be attributable to a progressive 
reduction of deep dyspareunia and pelvic pain. 
 Another field of application of DNG treatment is bladder endometriosis. A recent pilot study 
[35] on six patients treated for 12 months with DNG 2 mg/d showed an improvement of pain 
symptoms in all patients. In particular, urinary symptoms disappeared and at transvaginal 
ultrasound a significant decrease of bladder nodule size at 3- and 12-months evaluation was 
described. The potential beneficial effect of DNG on extragenital endometriosis has been evaluated 
in a small Japanese case series [36], in which four women with rectoisigmoidal endometriosis and 
one with bladder disease were enrolled. All patients received DNG at the standard daily dosage (2 
mg/d) for over 6 months. For all cases, a relief in pain symptoms and a lesion size reduction at 
ultrasonography were confirmed at follow-up. 
 Finally, a recent prospective study [37] evaluated the effectiveness of DNG on 30 patients 
with deep infiltrating endometriosis. After one year of treatment there was a significant 
improvement in all pain symptoms, including deep dyspareunia, without a reduction in the volume 
of endometriotic lesions at transvaginal sonography. 
 The safety and efficacy of long-term use (52 weeks) of DNG at a daily dose of 2 mg have 
been investigated in a multicenter Japanese study on 135 patients with endometriosis [25]. The most 
common adverse effects observed during treatment were menorrhagia (71.9%), headache (18.5%), 
and constipation (10.4%). The severity of menorrhagia was mild in the majority of women (n = 82) 
and moderate in 15 cases. Breakthrough bleeding was the cause of two of the discontinuations and 
11 washouts. During the study period, there was a progressive decrease of abnormal bleeding, 
indicating a tendency to amenorrhea with the extension of the treatment period. In a pooled analysis 
of four randomized, controlled, European trials [38] the most common adverse reactions were 
headache (9%), breast discomfort (5.4%) depressed mood (5.1%), and acne (5.1%). The bleeding 
pattern was well-tolerated, and only the 0.6% of the enrolled women reported bleeding events as the 
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main cause for premature discontinuation. In addition, no significant variations were registered in 
serum levels of lipids, glycated hemoglobin and estradiol. These results were in line with those 
observed by Schindler et al. [39], whose study analyzed the safety of high-dose (20 mg/day) 
treatment with DNG for 24 weeks. Overall, DNG is a well-tolerated drug with a rate of 
discontinuation related to adverse reactions <5% [22].  
 The principal limitation to the widespread use of DNG as first-line treatment for 
endometriosis is its cost, higher than other progestins and combined oral contraceptive 
(COC) available on the market. In fact, in Italy, the annual cost of treatment with 2 mg/d of DNG is 
about 770 US $. Moreover, further studies should compare the efficacy of this drug with other 
progestins.  
2.3 DESOGESTREL 
Desogestrel (DSG) is a third-generation 19-nortesterone derivative progestin. DSG is a prodrug, 
which after oral administration is absorbed and converted to its active metabolite, Etonogestrel 
(ETN). The effects of DSG progestin-only pill (POP) on lipid and carbohydrate metabolism and 
hemostasis are derived from studies of comparison with levonorgestrel POPs [40] and showed a 
slight decrease of HDL-cholesterol, a minimal impact on carbohydrate metabolism, and a reduction 
of pro-coagulative activity. DSG-POP represents a safe contraceptive method (monthly ovulation is 
inhibited in 97% of users), and can be used during breastfeeding [41].  
 Few studies investigated the role of DSG in the treatment of endometriosis [42-45]. In 2007 
[42], continuous treatment with DSG-POP (75 μg) was compared to a COC (EE 20 μg + DSG150 
μg) for the treatment of 40 women with laparoscopically confirmed mild endometriosis (stage I and 
II). After 6 months of treatments, a significant improvement of pelvic pain was observed in both 
study groups, without between-group differences. The principal side effect reported in DSG group 
was breakthrough bleeding (4/20; 20%). The combination of DSG-POP and letrozole (2.5 mg/d), an 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ità
 de
gli
 St
ud
i d
i M
ila
no
] a
t 0
9:4
3 1
5 S
ep
tem
be
r 2
01
7 
Ac
ce
pte
d M
an
us
cri
pt
   11
aromatase inhibitor, for the treatment of stage IV endometriosis was tested in an open-label, 
prospective study [43]. A total of 12 women with persistent pelvic pain, not responding to previous 
surgical and medical therapy, were enrolled. Unfortunately, none of the patients completed the 6-
months treatment protocol, due to the development of functional ovarian cysts, with a median 
length of treatment of 84 days (range 56-112). This secondary effect could be ascribable to 
aromatase inhibitors. In fact, these compounds, block the conversion of androgens to estrogens in 
ovarian granulosa cells, with a consequent reduction of the negative feedback at the pituitary–
hypothalamus level, and therefore, increasing serum follicle-stimulating hormone levels that favor 
the growth of ovarian follicles [43]. During treatment, all the patients reported a significant 
improvement of dyspareunia and an amelioration of chronic pelvic pain. According to previous 
study the main adverse reaction was abnormal bleeding (75%), followed by weight gain (50%) and 
abdominal bloating (42%). In 2014, a patient preference trial [44] compared the contraceptive 
vaginal ring (EE 15 μg + etonogestrel 120 μg), administered cyclically, to the DSG-POP (75 μg/d) 
for the treatment of symptomatic women with rectovaginal endometriosis. The treatment period 
lasted 12 months; 60 women chose the DSG-only pill and 83 the vaginal ring. At the end of the 
study, the rate of satisfied women was higher in the group treated with DSG-POP (61.7% vs. 
36.1%). The discontinuation rate and the reduction in volume of rectovaginal nodules were similar 
in the two study groups. Gastrointestinal symptoms, chronic pelvic pain and deep dyspareunia were 
improved more in the DSG-POP group. Finally, a second patient preference trial [45] evaluated 
patient satisfaction after 6 months of treatment with DSG-POP (75 μg/d) and cyclic COC (EE 20 μg 
+ DSG 150 μg) in patients with symptomatic rectovag,inal endometriosis and migraine without 
aura. 62 women chose the DSG-only pill and 82 the COC, the withdrawal rate was higher in the 
COC group (24.4% versus 11.3%); the main cause of interruption in DSG-POP group was erratic 
bleeding (n = 5; 8%). Satisfaction rate was higher in POP group (61.2% versus 37.8%), a significant 
improvement in QoL, both in terms of mental and physical components, was demonstrated with 
DSG treatment. In addition, the severity and number of migraine attacks were significantly different 
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between baseline and 6-month treatment in POP group (P < 0.001) but not in COC group (P = 
0.078). Regarding pain symptoms both treatments were equally effective.  
         2.4 CYPROTERONE ACETATE 
Cyproterone acetate, a 17-hydroxyprogesterone derivative with antiandrogenic and 
antigonadotropic properties, represents one of the first progestins adopted for the treatment of 
endometriosis. In 1996, Moran et al. [46] performed a pilot study on seven women with 
laparoscopically confirmed endometriosis, with the aim of evaluating the effectiveness of a 6-month 
cyclical cyproterone acetate regimen (10 mg/d for 20 days, followed by 10 days without 
medication). Dysmenorrhea improved in all study subjects. At the end of the treatment, a second-
look laparoscopy showed an amelioration of the endometriosis stage. Finally, a RCT [47] compared 
the efficacy and safety of low-dose cyproterone acetate (12.5 mg/d) versus a COC (EE 0.02 mg + 
DSG 0.15 mg). Both treatments were administered continuously for 6 months. Ninety patients with 
recurrent moderate or severe pelvic pain after conservative surgery for endometriosis were enrolled. 
Overall, at the end of treatment, 73% of the women in the cyproterone acetate group were satisfied 
or very satisfied compared with 67% in the COC group. Both treatments were equally effective in 
reducing pain symptoms and enhancing QoL and sexual satisfaction. The withdrawal rate was 
similar (nine and six patients); the main side effects causing suspension of the treatment in the 
cyproterone acetate group were bloating (n = 1), decreased libido (n =1), depression (n =1), and 
headache (n = 1). Interestingly, seven women in the cyproterone acetate group reported a 
substantial reduction in libido, probably due to the antiandrogenic properties of the compound. The 
mean weight gain was comparable between the two study groups (2.4 ± 0.5 kg in the progestin 
group versus 2.2 ± 0.4 kg in the COC group). Regarding blood pattern, amenorrhea was reached in 
two thirds of women under progestin therapy and in about half of those taking COC. No major 
variations in serum lipid profiles were detected in either study group.  
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3. DEPOT PROGESTINS 
3.1 DEPOT MEDROXYPROGESTERONE ACETATE (DMPA) 
Medroxyprogesterone acetate is a 17OH-progesterone derivative available as a depot formulation 
(DMPA), which can be administered intramuscularly or subcutaneously every three months. DMPA 
is a highly effective and inexpensive contraceptive method that has been adopted worldwide for 
several decades [48].  
 First evidence of the use of DMPA for the treatment of endometriosis are dated back 1996, 
when Vercellini et al. [49] performed a RCT comparing intramuscular DMPA (150 mg/3 months) 
to a combination of cyclic COC and low-dose oral danazol (50 mg/d) for the treatment of pelvic 
pain in women with endometriosis. The compounds were administered for one year; a total of 80 
women were enrolled, 40 subjects were allocated in each study group. Overall, at the end of 
treatment, 72.5% of the women in the DMPA group were satisfied or very satisfied compared with 
57.5% in the COC plus danazol group. A significant decrease was demonstrated in all symptoms 
scores in both study groups without significant between-group differences. A total of eleven women 
withdrew from the study (four in DMPA group and seven in COC plus danazol group). The main 
side effects in DMPA arm concern menstrual pattern, with eight women out of ten reporting 
breakthrough bleeding (15%) and spotting (65%). In addition, the median time to return of regular 
menstrual flow in women who received DMPA was seven months, with a maximum delay of 1 
year. Finally, in both arms, a significant reduction in high-density lipoprotein cholesterol was 
observed. 
 Two large multicenter, evaluator-blinded, comparator-controlled trial [50,51] confront 
subcutaneous administration of DMPA 104 mg/0.65 ml (DMPA-SC) with leuprolide acetate, given 
every three months for six months, with 12 months of post-treatment follow-up. In both studies 
DMPA-SC was statistically equivalent to GnRHa in reducing pain symptoms after 12 months’ 
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follow-up. Significant improvements in QoL, evaluated through EHP-30 and SF-36 scales, occurred 
in both treatment groups. Moreover, women in DMPA-SC arm referred a significant amelioration in 
their sexual relationship at month 6 [50]. Patients in the DMPA-SC group showed significantly less 
BMD loss than did leuprolide patients at month 6. In addition, BMD levels return to pretreatment 
levels at 12 months’ follow-up in the DMPA-SC group but not in the leuprolide group. Regarding 
side effects, DMPA-SC was associated with fewer hypoestrogenic symptoms but more irregular 
bleeding, varying from light spotting to uterine hemorrhage. However, the discontinuation rate 
secondary to adverse events was low (2% in DMPA-SC group and 1.4% in leuprolide group) [50].    
 A RCT compared intramuscular DMPA (150 mg/3 months) with levonorgestrel-releasing 
intrauterine system (LNG-IUS) for the treatment of patients with moderate and severe 
endometriosis [52]. A total of thirty patients after conservative surgery for endometriosis underwent 
randomization; the treatment period lasted three years. A lumbar and hip DEXA scan was repeated 
yearly. Both treatments were effective in the management of pain symptoms through the study 
period. The only domains where no amelioration was observed were dyspareunia and urinary/bowel 
symptoms. No recurrences of lesions were detected at transvaginal ultrasound in both therapeutic 
groups. The drop-out rate was higher in DMPA group (53% versus 13%). The two main causes of 
discontinuation among the eight patients that interrupted DMPA were prolonged vaginal spotting (n 
= 3) and significant bone loss over lumbar spine (n = 2).     
 One of major sources of concerns regarding prolonged use of DMPA is the decrease of 
BMD and the increase risk of fracture, due to estrogen deficiency accompanying its use. Several 
studies have reported a reduction in BMD in DMPA users [53-62]. The greatest loss occurs during 
the first two years of treatment, and then BMD levels become stable [63-65]. In 2004, the FDA 
published a “black box warning” [66], and the Health Canada issued an advisory [67], 
recommending providers to adopt DMPA only if other methods were unsuitable or unacceptable 
and to limit its use to the shortest time possible, limiting its maximum use to 2 years. However, the 
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reversibility of the negative impact of DMPA on BMD toward or to baseline values within two 
years after discontinuation has been demonstrated in numerous studies [59,61,65,68]. Regarding the 
risk of fracture, two large-scale, population-based, case-control studies [69,70] showed a modest 
increase in the risk in DMPA users, particularly in long term users (ORs ≤ 1.5). These results were 
not confirmed in a large retrospective cohort study on more than 1.7 million women-years [71]. 
Further studies are needed to estimate the effect of DMPA use on the risk of fractures. Despite these 
premises, according to the American College of Obstetricians and Gynecologists 
(ACOG) [48] and WHO recommendations [72] the benefits of DMPA use surpasses the risks. 
3.2 LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) 
The LNG-IUS releases levonorgestrel, a potent 19-nortesterone derivative, directly into the uterine 
cavity at a relatively constant rate of 20 μg/day over a 5-year period [73]. The LNG-IUS induces 
profound effects on the eutopic endometrium, which became atrophic and inactive, whereas 
ovulation is usually not inhibited [74]. In fact, anovulatory rates varies from 70-85% in the first 
months of use to 15-40% after that [75]. The plausible mechanisms at the basis of LNG-IUS use in 
endometriosis field comprehend the induction of endometrial glandular atrophy, an extensive 
decidual transformation of the stroma, the downregulation of endometrial cell proliferation, and the 
intensification in apoptotic activities [74]. Moreover, the ameliorative effects of LNG-IUS on 
endometriosis’ symptoms are likely modulated through a decrease in the expression of glandular 
and stromal estrogen (α and β) and progesterone receptors in the ectopic endometrium [76, 77]. In 
addition, LNG-IUS increased Fas expression in both eutopic and ectopic endometrium of patients 
with endometriosis [76]. 
 One of the first studies evaluating the effectiveness of LNG-IUS in the treatment of 
endometriosis was performed on 11 women with symptomatic rectovaginal endometriosis [78]. At 
1-year follow-up the severity of all pain symptoms, including deep dyspareunia and dyschezia, 
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improved. Rectovaginal lesions size, evaluated through transrectal and transvaginal ultrasound, was 
significantly reduced after six months of therapy. 
 Moreover, the LNG-IUS has been evaluated in numerous RCTs for the treatment of 
symptomatic endometriosis (Table 3), with positive results. In particular, a Brazilian multicenter 
trial [80] compared the efficacy of the LNG-IUS and a depot GnRHa in 82 women with 
symptomatic endometriosis. At 6-months follow-up both treatments appeared to be similarly 
effective for endometriosis-related chronic pelvic pain, with a six-points decrease from baseline in 
VAS pain score in both study groups. At the end of the study, the 13% (n = 5) of patients in the 
LNG-IUS group and the 14% (n = 6) in the GnRHa group failed to reach a VAS pain score of less 
than three. In both treatment groups, the subgroup of patients that achieved the more rapid 
improvement in VAS score was the one of patients with stage III and IV of the disease.  
 The long-term efficacy of LNG-IUS in the management of endometriosis has been evaluated 
in a retrospective study [85], that showed the ability of the device in providing symptoms control 
throughout a 3-year study period. These results are in line with those obtained in a RCT [52] that 
compared LNG-IUS with DMPA in the long-term treatment (36 months) of patients with moderate 
and severe endometriosis.  
 As above mentioned, in the majority of patients, LNG-IUS is unable to suppress ovulation, 
raising concerns for the risk of endometrioma recurrence, in line with the theory of endometriomas 
originating from corpora lutea [86]. Moreover, women treated with the device are prone to develop 
functional ovarian cysts [87] that could be misdiagnosed with ovarian endometriomas. Few studies 
have evaluated the long-term effectiveness of the device for the prevention on endometrioma 
recurrence. In the RCT of Wong et al. [52] no recurrences were identified; however, the sample size 
was small (n =15) and the number of patients that continued the study throughout the whole follow-
up period was even minor (n = 13). These outcomes are superimposable to those obtained by 
Tanmahasamut et al. [83], that did not identify any endometrioma recurrence after 12 months of 
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treatment with LNG-IUS. Two retrospective studies [88,89] compared the efficacy of postoperative 
use LNG-IUS with COC for preventing endometrioma recurrence. In both cases, postoperative 
LNG-IUS use seems comparable to that of COC in preventing endometrioma recurrence. On the 
contrary, another retrospective study [90] reported a cumulative postoperative endometrioma 
recurrence rate of 25% at 5-year follow-up. Accordingly, a recent RCT [84] showed a comparable 
endometrioma recurrence rate at 30-months’ follow-up between women allocated in LNG-IUS 
group (10/40, 25%) and those in the expectant management group (15/ 40, 37.5%) (95% confidence 
interval: 0.27-1.33, P = 0.2). In both study groups, patients received an initial treatment, after 
laparoscopic cystectomy, with six cycles of GnRHa. The number of recurrent endometriotic cysts 
necessitating a second surgical intervention or hormone treatment was significantly higher in the 
control group (8/40, 20% versus 1/40, 2.5%).  In line of recent evidence, we believe that the 
potential role of LNG-IUS in the prevention of endometrioma recurrence should be reconsidered, 
and an appropriate counseling with the patient on this risk is the needed prior to device insertion. 
 Therefore, the best candidates for this treatment modality seem to be women who have 
already completed their family project or wish to postpone pregnancy, whose main symptom is 
dysmenorrhea, who are in their forties, and who do not tolerate progestins used systemically [1]. 
Moreover, women should be informed that during the first months of treatment, significant 
menstrual bleeding abnormalities, including spotting and even menorrhagia, are expected. Whereas, 
after the first year of use, almost 20-30% of patients became amenorrheic [74]. 
3.3 ETONOGESTREL SUBDERMAL IMPLANT  
The etonogestrel (ENG) subdermal contraceptive implant is a device containing 68 mg of ENG and 
is currently approved by the FDA for three years of use. Recent data suggest extended contraceptive 
efficacy to at least five years [91,92]. The implant should be inserted sub-dermally in the upper arm. 
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 Few data are available on the use of this device for the treatment of endometriosis and the 
majority came from case reports and case series [93-95]. In 2005, Ponpuckdee et al. [96] evaluated 
the efficacy of ENG-subdermal implant in the treatment of fifty symptomatic women with 
surgically confirmed endometriosis, with an improvement of pain severity and a high satisfaction 
rate (80%). The follow-up lasted only 12 weeks, and 30% of the patients reported spotting and 
breakthrough bleeding. Walch et al. [97] conducted a RCT with the aim of comparing the 
therapeutic efficacies of ENG-subdermal implant (n = 21) and DMPA (n = 20) concerning pain 
relief in forty-one women with symptomatic endometriosis. During the 1-year follow-up, a 
substantial improvement in pain intensity was recorded in both study groups; after 6-months, the 
average reduction in pain was 68% in the ENG-subdermal implant group and 53% in the DMPA 
group. The overall satisfaction rate was almost identical in the two groups (57% in the ENG group 
versus 58% in the DMPA group). The percentage of withdrawal was higher in DMPA group (35%, 
n = 7) compared to ENG group (19%, n = 4). The principal cause of interruption in the latter group 
was unbearable bleeding irregularities (n = 2). 
 The effect of ENG-implant on BMD have been evaluated in a prospective comparative study 
in 2000 [98]. The effect of ENG-implant on BMD was compared to a non-hormone medicated IUS. 
Changes from baseline on the ENG-group were comparable from those in the IUS group. 
Contrarily, Bahamondes et al. [99] demonstrated a significantly decrease in BMD at the midshaft of 
the ulna after 18 months from the insertion of the device.  
 In March 2016, the FDA published a warning regarding the risk of migration of the implant 
within the arm from the insertion site, due to deep insertion of the implant [100]. In addition, there 
have also been post-marketing reports of implants migrated within the vessels of the arm and the 
pulmonary artery, which request an endovascular or surgical procedure for the removal. The FDA 
recommends the removal of the implant, prior identification of the site of migration if the device 
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cannot be palpated. The frequency of migration of radiopaque implant is 1.3/every millions of 
inserted devices [101]. 
4. CONCLUSIONS 
 Progestins therapies adopted for the treatment of endometriosis include a wide range of 
therapeutic options (Table 4), that appear effective in the management of pain symptoms associated 
with the disease but differ considerably regarding their cost and side-effects profile.  
 Advantages of depot preparations include avoidance of need of repeated administration, 
effective contraception, and absence of hepatic first-pass metabolic effect. In addition, absorption is 
not affected by episodes of diarrhea or vomiting and the continuous delivery maintains constant 
plasma drug levels and eliminates the peaks and troughs associated with the oral administration. 
The main disadvantage of depot compounds, contrarily to oral drugs, is the impossibility to 
promptly interrupt treatment in the event of adverse effects. This drawback seems particularly 
important in case of treatment with DMPA, where uterine breakthrough bleeding can be prolonged 
and difficult to correct. Moreover, with DMPA, a prolonged delay in the resumption of ovulation 
has been observed. Thus, this kind of treatment should be reserved for women with persistent or 
recurrent pain after hysterectomy for endometriosis [1]. 
 Given the chronicity of endometriosis disease, the treatment of choice should ideally be 
taken until the establishment of menopause. In addition, endometriosis should not be seen as a 
unique disease, and a specific treatment for different endometriotic localizations should be 
considered. OCs may be first considered for women with endometriomas while progestins may be 
favored for those with deep endometriosis. This latter form of the disease deserves more careful 
management because of the possible clinical consequences. In fact, deep endometriosis could be 
defined as the truly severe endometriotic disease [1]. Noteworthy, these lesions commonly 
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infiltrates into richly innervated anatomic sites, and the presence of mast cells in deep nodules is 
more common compared to those in ovarian and superficial peritoneal lesions [1]. 
It appears of fundamental importance an appropriate counseling of the patient, in order to consider 
patient’s preference and to provide a comprehensive overview of the available treatments and their 
relative effectiveness, side effects, and cost. In line with this view, the economic burden represents 
the main obstacle to the widespread of dienogest diffusion, in spite of the good outcomes in terms 
of pain management. The treatment should be tailored for every woman with preference to the most 
cost-effective compound, depending on the most complained symptom, disease location, and the 
need for contraception.  
 In other words, the clinical approach should be more patient-oriented than drug-oriented. 
There is not the best drug but, conversely, the best drug for this specific woman, a drug that 
minimizes the side effects deemed relevant for this particul r woman and that consents to ensure 
long-term adherence. The cornerstone of endometriosis treatment is the long-term adherence of the 
patient to the treatment. In this optic, side-effects, costs and effectiveness should receive equal 
consideration. Low costs of medication and a favorable side-effects profile can play a crucial role 
for long-term adherence to treatment [1,11]. Moreover, shift from one agent to another during life 
should not be considered a failure. Definitely abandoning medical treatment is the real failure 
because it exposes wom n to recurrences and possible demanding and risky subsequent surgeries.   
   
5. EXPERT OPINION  
Endometriosis can be effectively controlled even if not definitely cured. Progestins are effective in 
controlling pain symptoms in approximately three out of four women with endometriosis, and their 
effect seems not inferior to that achieved with other compounds used to treat the disease, such as 
GnRHa [1]. Available progestins used in the treatment of endometriosis include a broad range of 
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both oral and depot compounds, and represent, in most cases, an inexpensive alternative treatment 
option. In addition, progestins do not increase significantly thrombotic risk and could be adopted in 
those women with metabolic or cardiovascular contraindication to estrogen-progestins [11]. 
 However, many issues on medical management of endometriosis are still open and require a 
definitive answer, such as whether progestins are superior to estrogen-progestins, or one progestin 
is more effective or better tolerated than another, particularly in those patients with deep infiltrating 
lesions. As a matter of fact, we need more data from comparative studies among progestins in order 
to provide more valuable information to women. Unfortunately, this aspect has been up to now 
neglected (Figure 1). In addition, the efficacy (i.e., which one works better under ideal and highly 
controlled conditions, such as in an RCT) on the disease seems to be similar among drugs but the 
effectiveness (i.e., whether one drug works better than the other in real life, that is, under non-ideal 
circumstances) may radically differ. Of particular relevance, here is the need for real life studies. 
RCTs are obviously outstanding evidence, but they do not provide information on adherence. 
Future research should also focus on alternative routes for drug administration, such as the 
intravaginal one. In endometriosis field, the vagina represents a scarcely explored route for drug 
delivery, and the majority of available evidence came from studies on danazol and the estrogen-
progestin contraceptive vaginal ring. However, advantages of the vaginal administration are several, 
such as the reduction of daily dosages, the continuity of drug release, the avoidance of the hepatic 
first-pass effect, and the possibility of extending the interval between doses, all factors that taken 
together could enhance patient’s adherence to the drug regimen [104]. Moreover, is plausible to 
hypothesize that a local administration near the endometriotic nodules could result in higher 
concentrations of the drug in the surrounding area, with the potential result of a “target lesion” 
therapy. 
 The “definite” drug, i.e. the drug that could definitely eradicate endometriosis is not in our 
hands and will not be available in the next future. The main obstacle to research in this field is our 
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ignorance of the real causes of the disease. Progresses have been made in our understanding of the 
pathogenetic mechanisms but the causes remain obscure. In fact, new options that are foreseen for 
the management of endometriosis act on specific pathogenetic mechanisms and are thus not 
expected to overcome the need for long-term use that is the most important drawback of progestins 
[105]. Given their inevitably extremely higher costs consequent to the financial effort for their 
development and the generally favorable side-effects profile of progestins, the new agents are 
inherently intended to become second line treatments, i.e. agents to be used when progestins are 
ineffective or non-tolerated.  
 For future studies, we plea for a radical shift of the study design for the development of new 
agents for endometriosis. In particular, we argue against the commonly used superiority RCTs 
against placebo to demonstrate effectiveness and non-inferiority RCT against GnRH analogues to 
support clinical relevance. Even if these type of studies are required by some main authorities such 
as the Food and Drug Administration (FDA) to allow registration, they are of scant clinical interest 
[106]. Firstly, we should remember the existence of the placebo-effect, especially on trials, whose 
main objective is pain relief. Therefore, blinding is mandatory for any study addressing this issue; 
however, we have to underline that an ideal placebo for a treatment affecting menstruation is very 
arduous to realize. Moreover, allocating suffering women to a placebo arm is ethically questionable, 
and it has already been repeatedly demonstrated that any drug is better than placebo for pain relief 
[102,103]. Secondly, one may also question the use of GnRH agonists as comparator in non-
inferiority trials. GnRH agonists are highly effective drugs but they cannot be administered for 
more than six months because of side-effects and endometriosis typically relapse once they are 
discontinued. A new compound that would be slightly less effective than GnRH agonists but that 
would consent long term safe use and even pregnancy seeking would be discarded by the FDA 
policy despite this advantageous profile.   
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ARTICLE HIGHLIGHTS  
• Endometriosis is an estrogen-dependent chronic inflammatory disorder of fertile age that 
requires a chronic treatment. Long-term adherence to treatment is pivotal to ensure an 
effective clinical management. 
• Progestins act through the inhibition of inflammatory pathways and responses, provoking 
apoptosis in endometriotic cells. Moreover, this class of drug stimulate atrophy or regression 
of endometrial lesions, induce anovulation, inhibit angiogenesis, and decrease expression of 
matrix metalloproteinases, thus diminishing the invasiveness of endometriotic implants.  
• Available progestins adopted in the management of endometriosis include a wide range of 
both oral and depot compounds, and represent, in most cases, an inexpensive treatment 
option. 
• As there are not enough robust data demonstrating the superiority of one progestin over the 
others, the first choice should be low-dose oral norethisterone acetate, given the extremely 
favorable cost-effectiveness profile. 
• Future researches on progestins in the treatment of endometriosis should focus on 
comparison trials with others progestins or estrogen-progestins, and should be designed as 
superiority trials. Do
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Table 1. List of progestins utilized for medical treatment of endometriosis. 
 
Drug Chemical structure Route of administration  Cost 
a
Cyproterone acetate (CPA) 17-OH progesterone derivative Oral 24,00 € (25 pills of 50 mg) 
Desogestrel (DSG) 19-nortesterone derivative Oral 9,90-15,40 € (28 pills) 
Dienogest (DNG) 19-nortesterone derivative Oral 56,00 € (28 pills) 
Etonogestrel (ENG) 19-nortesterone derivative Subdermal implant 195,00 € (lifespan 3 years) 
Levonorgestrel (LNG) 19-nortesterone derivative Intrauterine device 242,00 € (lifespan 5 years) 
Depot Medroxyprogesterone acetate (DMPA) 17-OH progesterone derivative Intramuscular, subcutaneous 8,70 € (lifespan 3 months) 
Norethisterone acetate (NETA) 19-nortesterone derivative Oral 5,68 € (30 pills of 10 mg) 
 
a Based on the Italian market  
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Table 2. Effect of dienogest (DNG), as assessed in comparative studies on the treatment of symptomatic endometriosis (literature data, 2002–2016). 
Source Study design Number 
of 
patients 
enrolled 
Study drug Comparator Treatment 
period 
Follow-up 
period 
Outcome
Cosson et al., 2002 
[28] 
RCT 142 DNG 2 mg/day per os 
(n = 74) 
Triptorelin 3.75 mg 
depot i.m. 
injections/28 days      
(n = 68) 
4 months 12 months 
(reproductive 
outcome 
only) 
Similar postoperative pain 
relief during treatment; no 
pain evaluation at 12 
months follow-up 
Harada et al., 2009 
[29] 
RCT 271 DNG 2 mg/day per os 
(n = 137) 
Buserelin 900 
mg/day i.n.            
(n = 134) 
6 months No follow-up Similar pain relief and 
improvement in QoL. More 
bleeding, but less hypo-
estrogenic side effects and 
BMD loss with DNG. 
Strowitzki et al., 
2010 [26] 
RCT 252 DNG 2 mg/day per os 
(n = 124) 
Leuprolide 3.75 mg 
depot i.m. 
injections/28 days 
(n = 128) 
6 months No follow-up Similar pain relief. Higher 
improvement in QoL with 
DNG. More bleeding but 
less hypo-estrogenic side 
effects and BMD loss with 
DNG.  
Morotti et al., 2014 
[32] 
Open-label 
prospective 
studya 
25 DNG 2 mg/day per os 
(n = 25) 
NETA 2.5 mg/day 
per os (n = 25) 
12 months 
(6 months 
of NETA + 
6 months 
of DNG) 
No follow-up Improvement of pain 
symptoms, sexual function, 
QoL and satisfaction with 
DNG  
Oh et al., 2015 [31] Retrospective 218 DNG 2 mg/day per os 
(n = 98) 
MPA 30-60 mg/day 
per os (n = 120) 
6 months No follow-up Higher pain relief with 
DNG. More bleeding, 
alopecia, and headache 
with DNG. More weight 
gain, depression and breast 
tenderness with MPA. 
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Source Study design Number 
of 
patients 
enrolled 
Study drug Comparator Treatment 
period 
Follow-up 
period 
Outcome 
Takaesu et al., 
2016 [30] 
RCT 111 DNG 2 mg/day per os 
(n = 56) 
Goserelin 1.8 mg 
depot s.c. 
injections/28 days 
(n = 55) 
24 weeks 24 months No difference in post-
operative endometriosis 
recurrence rate. Similar 
pain relief, but fewer side 
effects with DNG. 
Vercellini et al., 
2016 [21] 
Before-after 
study 
90 DNG 2 mg/day per os 
(n = 90) 
NETA 2.5 mg/day 
per os (n = 90) 
6 months No follow-up Similar satisfaction with 
treatment, frequency of 
irregular bleeding and pain 
relief. Comparable 
improvements in QoL and 
sexual functioning. Better 
tolerability with dienogest. 
Higher discontinuation rate 
with DNG (owing to drug 
cost) 
Lee et al. 2016 [24] RCT 64 DNG 2 mg/day per os 
(n = 36) 
Leuprorelin acetate 
3.75 mg s.c. 
injections/28 days + 
NETA 0.5 mg/day 
or estradiol             
1 mg/day per os          
(n = 28) 
6 months No follow-up Similar pain relief. 
Comparable QoL 
improvements. Similar 
lumbar spine BMD loss in 
both groups (-2.5% for 
GnRHa plus add-back 
therapy and -2.3% with 
DNG) 
 
a This study specifically selected patients with symptomatic rectovaginal endometriosis who had pain persistence and were unsatisfied after 6-
months of treatment with NETA. 
BMD, bone mineral density; DNG, dienogest; i.m., intramuscular; i.n., intranasal; MPA, medroxyprogesterone acetate; NETA, norethisterone 
acetate; QoL, quality of life; RCT, randomized controlled trial; s.c., subcutaneous 
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Table 3. Summary of randomized controlled trials on the use of LNG-IUS for the treatment of pain symptoms associated with endometriosis. 
Source Number 
of 
patients 
enrolled 
Study drug Comparator Follow-up 
period 
Outcome
Vercellini et al., 2003 [79] 40 LNG-IUS        
(n = 20) 
Expectant management after 
laparoscopic treatment of 
endometriotic lesions (n =20) 
12 months Greater pain relief with LNG-IUS. Lower 
recurrence rate of dysmenorrhea in LNG-IUS 
group. Higher patient satisfaction rate with LNG-
IUS. 
Petta et al., 2005 [80] 82 LNG-IUS        
(n = 39) 
Leuprolide 3.75 mg depot i.m. 
injections/28 days (n = 43) 
6 months Similar pain relief and psychological well-being. 
More bleeding with LNG-IUS.  
Wong et al., 2010 [52] 30 LNG-IUS        
(n = 15) 
DMPA 150 mg i.m. injections/3 
months (n = 15) 
36 months Similar symptoms control and lesions recurrence 
rates. Irregular vaginal bleeding common in both 
group; frequency and severity of bleeding worse 
with DMPA. Improvement of BMD with LNG-
IUS. Decline of BMD with DMPA. Better 
compliance in LNG-IUS group. 
Ferreira et al., 2010 [81] 44 LNG-IUS        
(n = 22) 
Leuprolide 3.75 mg depot i.m. 
injections/28 days (n = 21) 
6 months Similar pain relief. Significant reduction in VCAM, 
CRP, total cholesterol, triglycerides, LDL-C and 
HDL-C levels in LNG-IUS group. 
Bayoglu Tekin et al., 2012 
[82] 
40 LNG-IUS (n 
= 20) 
Goserelin 3.6 mg depot s.c. 
injections/28 days (n = 20) 
36 weeks 
(24 weeks  
of active 
treatment) 
Similar pain relief at 1,3 and 6 months’ follow-up; 
at 1 year follow-up patients treated with GnRHa 
had lower pain score compared with those treated 
with LNG-IUS. Higher patient satisfaction rate 
with GnRHa. More bleeding with LNG-IUS. 
Tanmahasamut et al., 2012 
[83] 
55 LNG-IUS (n 
= 28) 
Expectant management after 
laparoscopic treatment of 
endometriotic lesions (n =27) 
12 months Greater pain relief (dysmenorrhea and chronic 
pelvic pain) with LNG-IUS. Similar dyspareunia 
relief. Lower recurrence rate of dysmenorrhea in 
LNG-IUS group. Improvement in QoL in women 
treated with LNG-IUS. 
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Source Number 
of 
patients 
enrolled 
Study drug Comparator Follow-up 
period 
Outcome
Chen YJ et al., 2017 [84] 80 GnRHa 3.75 
mg depot 
i.m. 
injections/28 
days for 6 
months + 
LNG-IUS (n 
= 40) 
GnRHa 3.75 mg depot i.m. 
injections/28 days for 6 months + 
expectant management (n = 40) 
30 months Similar endometrioma recurrence rate at 30 
months’ follow-up between the two groups. Longer 
duration to dysmenorrhea recurrence in LNG-IUS 
group. Greater pain relief with LNG-IUS. Higher 
analgesic use in control group. Greater reduction of 
CA125 levels with LNG-IUS. Higher irregular 
vaginal bleeding in LNG-IUS group. 
 
DMPA, depot medroxyprogesterone acetate; LNG-IUS, levonorgestrel-releasing intrauterine system; QoL, quality of life; BMD, bone mineral density; VCAM, 
vascular cell adhesion molecule; CRP, C-reactive protein; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol. 
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Table 4. Advantages and disadvantages of progestins utilized for medical treatment of endometriosis. 
Drug Advantages Disadvantages  
Cyproterone acetate (CPA) - Improvement of pelvic pain symptoms  
- Regression of endometriotic lesions at 
second-look laparoscopy 
- No major variations in serum lipid profile 
- Low cost  
- High percentage of women reporting a 
decrease in libido among the side effect 
Depot Medroxyprogesterone acetate (DMPA) - Safe contraceptive method 
- Low cost 
- No-inferior to GnRHa in the management of 
pain symptoms 
- Prolonged, repeated and difficult to treat 
breakthrough bleeding 
- BMD loss 
- Prolonged delay in the resumption of 
ovulation 
Desogestrel (DSG) - Safe contraceptive method, even during 
breast-feeding 
- Effective in the treatment of endometriosis 
in patients with migraine 
- Breakthrough bleeding 
- Limited data  
Dienogest (DNG) - Superior to placebo and no-inferior to 
GnRHa in the treatment of symptomatic 
endometriosis 
- Combines the pharmacological properties of 
19-nortestosterone and derivatives of 
progesterone 
- Better tolerated than NETA 
- High cost 
- Inconsistent data on BMD 
- No RCTs against COC or other progestins 
Etonogestrel (ENG) - Safe contraceptive method 
- Low-cost 
- Extended-use to 5 year 
- Comparable to DMPA in the treatment of 
symptomatic endometriosis 
- Limited data 
- Risk of site migration  
- Inconsistent data on BMD 
 
Levonorgestrel (LNG) - Safe contraceptive method 
- Low cost (spread in a 5-year lifespan) 
- Fewer adverse effects than systemic 
progestins 
- During the first months after insertion 
menstrual irregularities may occur 
- Does not inhibit ovulation, risk of 
endometrioma recurrence 
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Drug Advantages Disadvantages  
- No-inferior to GnRHa in the treatment of 
symptomatic endometriosis 
 
Norethisterone acetate (NETA) - Low cost 
- Partly metabolized to estrogens, with 
positive effects on BMD 
- Improvement of pelvic pain symptoms  
- Effective in the treatment of deep 
dyspareunia, in particular in those women 
without deep lesions 
- Principal side effects are breakthrough 
bleeding, weight gain and decreased libido 
- Minor unfavorable changes in lipid profile 
(in particular with dosages > 10 mg/d) 
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